Ulrike Gnad-Vogt
Corporate Officer/Principal bei CUREVAC N.V.
Vermögen: 103 438 $ am 31.03.2024
Profil
Ulrike Gnad-Vogt is currently working as the Chief Medical Officer at CureVac SE since 2011.
Additionally, she holds the position of Senior Vice President & Head-Oncology at CureVac NV since 2011.
Dr. Gnad-Vogt obtained a doctorate degree from Universität des Saarlandes.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CUREVAC N.V.
0,02% | 31.03.2023 | 34 138 ( 0,02% ) | 103 438 $ | 31.03.2024 |
Aktive Positionen von Ulrike Gnad-Vogt
| Unternehmen | Position | Beginn |
|---|---|---|
| CUREVAC N.V. | Corporate Officer/Principal | 01.01.2019 |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 01.01.2011 |
Ausbildung von Ulrike Gnad-Vogt
| Universität des Saarlandes | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
